RT Journal Article
SR Electronic
T1 Heparin for Moderately Ill Patients with Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.08.21259351
DO 10.1101/2021.07.08.21259351
A1 Sholzberg, Michelle
A1 Tang, Grace H.
A1 Rahhal, Hassan
A1 AlHamzah, Musaad
A1 Kreuziger, Lisa Baumann
A1 Ní Áinle, Fionnuala
A1 Alomran, Faris
A1 Alayed, Khalid
A1 Alsheef, Mohammed
A1 AlSumait, Fahad
A1 Pompilio, Carlos Eduardo
A1 Sperlich, Catherine
A1 Tangri, Sabrena
A1 Tang, Terence
A1 Jaksa, Peter
A1 Suryanarayan, Deepa
A1 Almarshoodi, Mozah
A1 Castellucci, Lana
A1 James, Paula D.
A1 Lillicrap, David
A1 Carrier, Marc
A1 Beckett, Andrew
A1 Colovos, Christos
A1 Jayakar, Jai
A1 Arsenault, Marie-Pier
A1 Wu, Cynthia
A1 Doyon, Karine
A1 Andreou, E. Roseann
A1 Dounaevskaia, Vera
A1 Tseng, Eric K.
A1 Lim, Gloria
A1 Fralick, Michael
A1 Middeldorp, Saskia
A1 Lee, Agnes Y.Y.
A1 Zuo, Fei
A1 da Costa, Bruno R.
A1 Thorpe, Kevin E.
A1 Negri, Elnara Márcia
A1 Cushman, Mary
A1 Jüni, Peter
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/07/12/2021.07.08.21259351.abstract
AB Background Heparin, in addition to its anticoagulant properties, has anti-inflammatory and potential anti-viral effects, and may improve endothelial function in patients with Covid-19. Early initiation of therapeutic heparin could decrease the thrombo-inflammatory process, and reduce the risk of critical illness or death.Methods We randomly assigned moderately ill hospitalized ward patients admitted for Covid-19 with elevated D-dimer level to therapeutic or prophylactic heparin. The primary outcome was a composite of death, invasive mechanical ventilation, non-invasive mechanical ventilation or ICU admission. Safety outcomes included major bleeding. Analysis was by intention-to-treat.Results At 28 days, the primary composite outcome occurred in 37 of 228 patients (16.2%) assigned to therapeutic heparin, and 52 of 237 patients (21.9%) assigned to prophylactic heparin (odds ratio, 0.69; 95% confidence interval [CI], 0.43 to 1.10; p=0.12). Four patients (1.8%) assigned to therapeutic heparin died compared with 18 patients (7.6%) assigned to prophylactic heparin (odds ratio, 0.22; 95%-CI, 0.07 to 0.65). The composite of all-cause mortality or any mechanical ventilation occurred in 23 (10.1%) in the therapeutic heparin group and 38 (16.0%) in the prophylactic heparin group (odds ratio, 0.59; 95%-CI, 0.34 to 1.02). Major bleeding occurred in 2 patients (0.9%) with therapeutic heparin and 4 patients (1.7%) with prophylactic heparin (odds ratio, 0.52; 95%-CI, 0.09 to 2.85).Conclusions In moderately ill ward patients with Covid-19 and elevated D-dimer level, therapeutic heparin did not significantly reduce the primary outcome but decreased the odds of death at 28 days.Trial registration numbers: NCT04362085; NCT04444700Competing Interest StatementGrant funding for research. All authors have completed the ICMJE uniform disclosure form. Dr. Michelle Sholzberg reports grants from the Task 54, Defence Research Development Canada, Department of National Defence, Ottawa, Canada, St. Michael's Hospital Foundation, Toronto, Canada, St. Joseph's Health Centre Foundation, Toronto, Canada, The Ottawa Hospital Foundation COVID-19 Emergency Response Fund, Ottawa, Canada, International Network of Venous Thromboembolism Clinical Research Networks (INVENT) Kickstarter Award, P20 GM135007 from the National Institute of General Medical Sciences, NIH, University of Vermont Medical Center Fund Grant, College of Medicine Research Center, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia. Dr. Paula James reports funding from SEAMO (Southeastern Ontario Academic Medical Organization) COVID-19 Innovation Fund. Dr. Fionnuala Ní Áinle reports funding from the Science Foundation Ireland (SFI; the Irish national foundation for investment in scientific and engineering research). Dr. E. Roseann Andreou reports funding from 2020 TD Community Health Solutions Fund COVID-19 Research Grant, Michael Garron Hospital, Toronto, Canada.Clinical TrialNCT04362085; NCT04444700Clinical Protocols https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05076-0 Funding StatementThe RAPID Trial was funded by: Task 54, Defence Research Development Canada, Department of National Defence, Ottawa, Canada, St. Michael's Hospital Foundation, Toronto, Canada, St. Joseph's Health Centre Foundation, Toronto, Canada, 2020 TD Community Health Solutions Fund COVID-19 Research Grant, Michael Garron Hospital, Toronto, Canada, The Ottawa Hospital Foundation COVID-19 Emergency Response Fund, Ottawa, Canada, International Network of Venous Thromboembolism Clinical Research Networks (INVENT) Kickstarter Award, Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding Call 20/COV/0157, Southeastern Ontario Academic Medical Organization (SEAMO) COVID-19 Innovation Fund, P20 GM135007 from the National Institute of General Medical Sciences, NIH, University of Vermont Medical Center Fund Grant, College of Medicine Research Center, Deanship of Scientific Research, King Saud University, Riyadh, Saudi Arabia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics and regulatory approval were obtained at each of the participating centres in the RAPID trial. Ethical oversight and approval for the entire study was provided by the institutional review boards of Clinical Trials Ontario - St. Michael's Hospital, Comissão Nacional de Ética em Pesquisa, and Comitê de Ética em Pesquisa.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request in accordance with appropriate privacy and data sharing principles.